Review: Prophylactic use of granulocyte colony–stimulating factor reduces febrile neutropenia and short-term mortality in cancer

2008 ◽  
Vol 148 (1) ◽  
pp. 7
Author(s):  
David A. Frank
Keyword(s):  
Febrile Neutropenia ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Short Term ◽  
Short Term Mortality ◽  
Prophylactic Use ◽  
Stimulating Factor

scholarly journals Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland

2014 ◽  
Vol 6 ◽  
pp. 419-424
Author(s):  
Marek Wojtukiewicz ◽  
Ewa Chmielowska ◽  
Emilia Filipczyk-Cisarż ◽  
Krzysztof Krzemieniecki ◽  
Krzysztof Leśniewski-Kmak ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Clinical Practice ◽  
Febrile Neutropenia ◽  
Primary Prophylaxis ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Stimulating Factor

scholarly journals Granulocyte Colony Stimulating Factor (G-CSF) Induced Splenic Infarction in Breast Cancer Patient Treated with Dose-Dense Chemotherapy Regimen

2019 ◽  
Vol 2019 ◽  
pp. 1-4 ◽  
Author(s):  
Majed A. Alshamrani ◽  
Meteb Al-Foheidi ◽  
Ahmed H. Abdulrahim
Keyword(s):  
Breast Cancer ◽  
Febrile Neutropenia ◽  
Splenic Infarction ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Rare Side Effect ◽  
Splenic Biopsy ◽  
Dose Dense ◽  
Stimulating Factor ◽  
Factor G

Introduction. Granulocyte colony-stimulating factor (G-CSF) is commonly used for prevention and treatment of febrile neutropenia among solid tumor patients. It is considered an effective and relatively safe supportive care medication; however, it can cause rare and serious side effects such as spleen rupture or infarction. Case Presentation. We are reporting a case of a 27-year-old female with breast cancer who has been treated with dose-dense chemotherapy and received colony-stimulating factor as primary prevention of febrile neutropenia that was complicated halfway through with splenic infarction. This finding was confirmed by computed tomography (CT) scan and splenic biopsy. Management was conservative without the need of surgical intervention. Conclusion. Although splenic infarction is an extremely rare side effect of G-CSF, it can be a serious complication that should be recognized, monitored, and managed carefully.

Recent advances in the management of chemotherapy-induced neutropenia: biosimilar granulocyte colony-stimulating factor use in Italy

2020 ◽  
Vol 16 (14) ◽  
pp. 891-897
Author(s):  
Marco Danova ◽  
Paolo Pronzato ◽  
Ylenia Ingrasciotta ◽  
Andrea Antonuzzo ◽  
Ugo Trama ◽  
...  
Keyword(s):  
Febrile Neutropenia ◽  
Medical Oncology ◽  
Great Benefit ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Italian Association ◽  
Biological Products ◽  
National Congress ◽  
Chemotherapy Induced Neutropenia ◽  
Stimulating Factor

During the National Congress of the Italian Association of Medical Oncology, which was held in Rome, Italy, October 2019, experts met to discuss advantages of febrile neutropenia prevention based on biosimilar G-CSF. This issue is of paramount importance in oncology as recent biological products may be of great benefit, provided that costs are sustainable.

Sign in / Sign up

Export Citation Format

Share Document